Showing results (171-180 of 194) with videos related to

Sort By:
Pageof 20
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 12, 2024
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian CancerRanjit Manchanda, Li Sun, Monika Sobocan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerKrishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.
Cancer Research|November 15, 2023
R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication ConflictsZhiyan Silvia Liu, Sayantani Sinha, Maxwell Bannister, et al.
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Nucleic Acids Research|April 29, 2015
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancerJeremy Chien, Hugues Sicotte, Jian-Bing Fan, et al.
Cancer Research|July 29, 2021
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaKsenija Nesic, Olga Kondrashova, Rachel M Hurley, et al.
The Lancet. Oncology|December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialElizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Pageof 20